INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: BYR-52595 |   Pharmaceutics

Historical data: 2017 - 2023

Forecast period: 2025 - 2031

Quantitative units: Revenue in USD million and CAGR from 2025 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Influenza A Virus, H3N2 Subtype Infections Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET

7.1 GLOBAL INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)

8.1 GLOBAL INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

8.2 GLOBAL INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

9.1 GLOBAL INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

9.2 GLOBAL INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

10.1 GLOBAL INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)

10.2 GLOBAL INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)

11.1 NORTH AMERICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

11.2 NORTH AMERICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

11.3 NORTH AMERICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

11.4 NORTH AMERICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

11.5 NORTH AMERICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

11.6 NORTH AMERICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

12.1 EUROPE INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

12.2 EUROPE INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

12.3 EUROPE INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

12.4 EUROPE INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

12.5 EUROPE INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

12.6 EUROPE INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

13.1 ASIA PACIFIC INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

13.2 ASIA PACIFIC INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

13.3 ASIA PACIFIC INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

13.4 ASIA PACIFIC INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

13.5 ASIA PACIFIC INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

13.6 ASIA PACIFIC INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

14.1 LATIN AMERICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>

14.2 LATIN AMERICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

14.3 LATIN AMERICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

14.4 LATIN AMERICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

14.5 LATIN AMERICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

14.6 LATIN AMERICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA INFLUENZA A VIRUS, H3N2 SUBTYPE INFECTIONS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>

16.1 AbbVie Inc

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Inovio Pharmaceuticals Inc

16.3 Celltrion Inc

16.4 AIMM Therapeutics BV

16.5 ILiAD Biotechnologies LLC

16.6 Aphios Corporation

16.7 Medicago Inc

16.8 Glide Pharmaceutical Technologies Limited

16.9 FluGen Inc

16.10 Johnson & Johnson

16.11 Sarepta Therapeutics Inc

16.12 Zydus Cadila Healthcare Limited

16.13 MedImmune LLC

16.14 VBI Vaccines Inc

16.15 OPKO Health Inc

16.16 Mucosis BV

16.17 Visterra Inc

16.18 NanoViricides Inc

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

Market by Type :

NEO-8877
NP-025
NSC-61610
NVINF-1
Others

Market by Application :

Clinic
Hospital
Others

Companies

AbbVie Inc
Inovio Pharmaceuticals Inc
Celltrion Inc
AIMM Therapeutics BV
ILiAD Biotechnologies LLC
Aphios Corporation
Medicago Inc
Glide Pharmaceutical Technologies Limited
FluGen Inc
Johnson & Johnson
Sarepta Therapeutics Inc
Zydus Cadila Healthcare Limited
MedImmune LLC
VBI Vaccines Inc
OPKO Health Inc
Mucosis BV
Visterra Inc
NanoViricides Inc

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE
  • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY
  • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH
  • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING
  • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.